MTM(SH:688029) Sou Hu Cai Jing·2025-06-28 22:21Summary of Key Points Core Viewpoint - Nanwei Medical (688029) has adjusted its share repurchase price limit and announced a cash dividend distribution plan for shareholders, reflecting its ongoing commitment to shareholder value and market responsiveness [1]. Company Announcements - The company has lowered the upper limit of its share repurchase price from RMB 96.54 to RMB 95.54, effective from June 24, 2025 [1]. - The total amount allocated for the share repurchase is between RMB 30 million and RMB 50 million, with a repurchase period of six months from the board's approval date [1]. - Following the implementation of the 2024 annual profit distribution plan, the company will distribute a cash dividend of RMB 10.00 per 10 shares (including tax) to all shareholders [1]. - The adjusted number of shares to be repurchased is estimated to be between 523,341 and 314,005 shares, representing approximately 0.28% to 0.17% of the company's total share capital [1]. Market Performance - As of June 27, 2025, Nanwei Medical's stock closed at RMB 67.19, a 4.27% increase from the previous week's closing price of RMB 64.44 [1]. - The stock reached a weekly high of RMB 67.47 and a low of RMB 63.85 during the same period [1]. - The company's current total market capitalization is RMB 12.621 billion, ranking 20th out of 126 in the medical device sector and 1277th out of 5151 in the A-share market [1].